Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.87 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.87 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.67 |
| ▸ | APP | P05067 | 4/20 | 0.67 |
| ▸ | SNCA | P37840 | 4/20 | 0.67 |
| ▸ | TSHR | P16473 | 3/20 | 0.67 |
| ▸ | TP53 | P04637 | 1/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.67 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.67 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | DRD3 | P35462 | 2/20 | 0.54 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.54 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.54 |
| ▸ | RXRA | P19793 | 5/20 | 0.51 |
| ▸ | RARA | P10276 | 4/20 | 0.51 |
| ▸ | RARB | P10826 | 4/20 | 0.51 |
| ▸ | RARG | P13631 | 4/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2398379 | 1.00 | MAPT (0.87) | MAPTALOX15ALDH1A1CYP3A4APP | |
| Canthaxanthin SCHEMBL19618 | 0.93 | MAPT (1.00) | MAPTALOX15ALDH1A1CYP3A4APP | |
| Canthaxanthin SCHEMBL12920083 | 0.93 | MAPT (1.00) | MAPTALOX15ALDH1A1CYP3A4APP | |
| Canthaxanthin SCHEMBL8971840 | 0.93 | MAPT (1.00) | MAPTALOX15ALDH1A1CYP3A4APP | |
| SCHEMBL8128019 | 0.91 | MAPT (0.90) | MAPTALOX15ALDH1A1CYP3A4APP | |
| SCHEMBL8132702 | 0.91 | MAPT (0.90) | MAPTALOX15ALDH1A1CYP3A4APP | |
| SCHEMBL13252665 | 0.91 | MAPT (0.90) | MAPTALOX15ALDH1A1CYP3A4APP | |
| SCHEMBL2832602 | 0.90 | MAPT (0.92) | MAPTALOX15ALDH1A1CYP3A4APP | |
| SCHEMBL7759851 | 0.88 | MAPT (0.85) | MAPTALOX15ALDH1A1CYP3A4APP | |
| Canthaxanthin SCHEMBL419514 | 0.88 | MAPT (0.90) | MAPTALOX15ALDH1A1CYP3A4APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 147 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2167647-A2 | REGULATORY T CELLS AND METHODS OF MAKING AND USING SAME | LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY (US) | 2010-03-31 | — | — | EP | claimed |
| US-20090136470-A1 | REGULATORY T CELLS AND METHODS OF MAKING AND USING SAME | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-05-28 | — | — | US | claimed |
| WO-2008157394-A2 | REGULATORY T CELLS AND METHODS OF MAKING AND USING SAME | LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY (US) | 2008-12-24 | — | — | WO | claimed |
| US-20060281813-A1 | Methods of treating hyperproliferative cell disorders | RUBIN CHARLES | 2006-12-14 | — | — | US | claimed |
| EP-1628631-A2 | METHODS OF TREATING HYPERPROLIFERATIVE CELL DISORDERS | Achkar, Charles C. (US) | 2006-03-01 | — | — | EP | claimed |
| EP-1104294-B8 | COMPOSITIONS AND METHODS OF TREATING ABNORMAL CELL PROLIFERATION | LEO PHARMA AS (DK) | 2005-11-23 | — | — | EP | claimed |
| EP-1104294-B1 | COMPOSITIONS AND METHODS OF TREATING ABNORMAL CELL PROLIFERATION | LEO PHARMA A S (DK) | 2005-09-28 | — | — | EP | claimed |
| WO-2005000230-A2 | METHODS OF TREATING HYPERPROLIFERATIVE CELL DISORDERS | ACHKAR CHARLES (US) | 2005-01-06 | — | — | WO | claimed |
| US-6552009-B2 | Vitamin D analog and a retinoid, wherein: the retinoid is 4-oxo-retinol, 4-oxo- retinal, or 4-oxo-retinyl ester; also restoring the natural color of gray hair; treating hair and skin disorders | GENTRIX LLC | 2003-04-22 | — | — | US | claimed |
| EP-1104294-A4 | COMPOSITIONS AND METHODS OF TREATING ABNORMAL CELL PROLIFERATION | GENTRIX LLC (US) | 2003-02-05 | — | — | EP | claimed |
| US-20020183388-A1 | Use of retinoids plus histone deacetylase inhibitors to inhibit the growth of solid tumors | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-12-05 | — | — | US | claimed |
| WO-2002060430-A1 | USE OF RETINOIDS PLUS HISTONE DEACETYLASE INHIBITORS TO INHIBIT THE GROWTH OF SOLID TUMORS | CORNELL RESEARCH FOUNDATION, INC. (US) | 2002-08-08 | — | — | WO | claimed |
| US-20010049365-A1 | Vitamin D analog and a retinoid, wherein: the retinoid is 4-oxo-retinol, 4-oxo- retinal, or 4-oxo-retinyl ester; also restoring the natural color of gray hair; treating hair and skin disorders | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) | 2001-12-06 | — | — | US | claimed |
| EP-1104294-A1 | COMPOSITIONS AND METHODS OF TREATING ABNORMAL CELL PROLIFERATION | Achkar, Charles C. (US) | 2001-06-06 | — | — | EP | claimed |
| WO-2000003700-A1 | COMPOSITIONS AND METHODS OF TREATING ABNORMAL CELL PROLIFERATION | ACHKAR CHARLES C (US) | 2000-01-27 | — | — | WO | claimed |
| US-5962534-A | ACNE THERAPY | CORNELL RESEARCH FOUNDATION, INC. (US) | 1999-10-05 | — | — | US | claimed |
| US-20240058293-A1 | Nutritional Formulas Comprising Medium Chain Fatty Acids or Esters Thereof and Methods Related Thereto | UNIV EMORY (US) | 2024-02-22 | — | — | US | disclosed |
| US-11826336-B2 | Nutritional formulas comprising medium chain fatty acids or esters thereof and methods related thereto | EMORY UNIVERSITY (US) | 2023-11-28 | — | — | US | disclosed |
| US-4049718-A | Sulphones | RHONE-POULENC, S.A. (FR) | 1977-09-20 | — | — | US | disclosed |
| US-4048234-A | Sulphones | RHONE-POULENC S.A. (FR) | 1977-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010049365-A1 | Vitamin D analog and a retinoid, wherein: the retinoid is 4-oxo-retinol, 4-oxo- retinal, or 4-oxo-retinyl ester; also restoring the natural color of gray hair; treating hair and skin disorders | RBP4, VDR, CYP24A1 | MAPT 4178/4885ALOX15 970/4885ALDH1A1 234/4885 |
| US-20060281813-A1 | Methods of treating hyperproliferative cell disorders | HRAS, CDC73, MKI67 | MAPT 4706/4885ALOX15 1556/4885ALDH1A1 1302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.